Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines

This episode continues the discussion regarding the rapid evolution of mRNA technologies since COVID-19. Guests discuss the improvements that have occurred within just a few years, which are making these therapies more reliable, cost-effective and viable for personalized cancer, rare disease chronic disease treatment.Today’s episode is sponsored by Eclipsebio. From AI-ready datasets to sequencing validation, they drive RNA success.Explore their solutions at ⁠https://eclipsebio.com/⁠.Host⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuests⁠Andy Geall⁠, Co-founder and Chief Development Officer, Replicate Bioscience; Chair of the Board, Alliance for mRNA Medicines⁠Pad Chivukula⁠, Co-founder, CSO & COO, Arcturus TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.